# Safety, Pharmacokinetics and Efficacy Study of MP-214 in Patients With Schizophrenia

> **NCT00862992** · PHASE2 · COMPLETED · sponsor: **Tanabe Pharma Corporation** · enrollment: 34 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Cariprazine 3 mg
- **DRUG:** Cariprazine 6 mg
- **DRUG:** Cariprazine 12.5 mg

## Key facts

- **NCT ID:** NCT00862992
- **Lead sponsor:** Tanabe Pharma Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** 2009-09
- **Final completion:** 2009-09
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2026-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00862992

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00862992, "Safety, Pharmacokinetics and Efficacy Study of MP-214 in Patients With Schizophrenia". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT00862992. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*